The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis
BackgroundAvacopan is an oral selective C5a receptor inhibitor. It received FDA approval in October 2021 for use with standard glucocorticoid therapy to treat antineutrophil cytoplasmic antibody-associated vasculitis. However, there are limitations to understanding adverse events (AEs) in clinical p...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-10-01
|
| Col·lecció: | Frontiers in Immunology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654735/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|